Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: A single center experience
 
Yazarlar (15)
Hakan Goker Hacettepe Üniversitesi, Türkiye
Evren Ozdemir Hacettepe Üniversitesi, Türkiye
Burak Uz
Hacettepe Üniversitesi, Türkiye
Yahya Buyukasik Hacettepe Üniversitesi, Türkiye
Mehmet Turgut Ondokuz Mayis University, Medical School, Türkiye
Songul Serefhanoglu Hacettepe Üniversitesi, Türkiye
Salih Aksu Hacettepe Üniversitesi, Türkiye
Nilgun Sayinalp Hacettepe Üniversitesi, Türkiye
Ibrahim C. Haznedaroglu
Hacettepe Üniversitesi, Türkiye
Fatma Tekin Hacettepe Üniversitesi, Türkiye
Dr. Öğr. Üyesi Yasemin KARACAN Hacettepe Üniversitesi, Türkiye
Sevilay Unal
Hacettepe Üniversitesi, Türkiye
Eylem Eliacik Hacettepe Üniversitesi, Türkiye
Ayse Isik Hacettepe Üniversitesi, Türkiye
Osman I. Ozcebe
Hacettepe Üniversitesi, Türkiye
Makale Türü Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı Transfusion and Apheresis Science (Q4)
Dergi ISSN 1473-0502 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 12-2013
Cilt / Sayı / Sayfa 49 / 3 / 590–599 DOI 10.1016/j.transci.2013.07.030
Makale Linki https://doi.org/10.1016/j.transci.2013.07.030
Özet
Due to the high transplant related morbidity and mortality (TRM), relatively younger acute leukemia patients that have a good performance status and no comorbidity are eligible for myeloablative conditioning (MAC) followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT).The outcomes of 84 consecutive adult patients with ALL (n = 38) or AML (n = 46) who underwent allo-HSCT from their HLA-identical siblings were evaluated retrospectively. The median age at transplantation was 34 (17–58 years) for the whole patient population. Of these, 24 patients received a MAC and 60 patients received a fludarabine-based reduced intensity conditioning regimen (RIC).After a median follow-up of 32 months (range, 1–119), for the entire group, the 3-year estimated overall survival (OS) was 57.5% and the disease-free survival (DFS) was 51.5%. The OS for ALL and AML patients were 53.9% vs 62.1%: and …
Anahtar Kelimeler
Allogeneic hematopoietic stem cell transplantation | Graft-versus-host disease | Myeloablative conditioning regimen | Reduced intensity conditioning regimen